Home>>Signaling Pathways>> PROTAC>>Thalidomide 4'-oxyacetamide-PEG3-amine

Thalidomide 4'-oxyacetamide-PEG3-amine

Catalog No.GC50462

Thalidomide 4'-oxyacetamide-PEG3-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide 4'-oxyacetamide-PEG3-amine Chemical Structure

Cas No.: 2245697-84-9

Size Price Stock Qty
25mg
$84.00
In stock
100mg
$245.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Functionalized cereblon ligand for PROTACsup>® research and development; incorporates an E3 ligase ligand plus a PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 1 PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Winter et al (2015) Functionalized Cereblon ligand for PROTACs; incorporates an E3 ligase ligand and a linker used in PROTAC technology. Science 348 1376 PMID:25999370 |Salami et al (2017) Waste disposal-An attractive strategy for cancer therapy. Science 355 1163 PMID:28302825

Reviews

Review for Thalidomide 4'-oxyacetamide-PEG3-amine

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide 4'-oxyacetamide-PEG3-amine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.